Trial Bank
106 trials match
- OSSIA: A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
MSRelapsing and progressivePhase 4Recruiting
Genentech, Inc. · 2026 · 100 participants
- SONATA-MS: Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
MSRelapsing MSRecruiting
ocrelizumab · Hoffmann-La Roche · 2026 · 1,800 participants
- OLERO: A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
MSRelapsing and progressivePhase 3Running, not recruiting
ocrelizumab · Hoffmann-La Roche · 2022 · 1,300 participants
- OleroMAX: An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
MSMS (type not specified)Phase 3Recruiting
ocrelizumab · Hoffmann-La Roche · 2024 · 500 participants
- CLOU064C12306: Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
MSRelapsing MSPhase 3Recruiting
remibrutinib · Novartis Pharmaceuticals · 2025 · 400 participants
- StarMS: Stem cell transplantation versus disease modifying therapy (alemtuzumab or ocrelizumab) for patients with highly active relapsing remitting MS
MSRelapsing MSPhase 3Completed (inferred)
cyclophosphamide anhydrous, filgrastim, lenograstim · Sheffield Teaching Hospitals · 2020 · 198 participants
- PORTAMENTO: A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
MSRelapsing and progressivePhase 2Running, not recruiting
ocrelizumab · Hoffmann-La Roche · 2025 · 193 participants
- Operetta III: A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
MSRelapsing MSPhase 2Not yet recruiting
ocrelizumab · Hoffmann-La Roche · 2026 · 25 participants
- SurfSubQ: A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
MSRelapsing and progressiveRecruiting
ocrelizumab · Hoffmann-La Roche · 2024 · 842 participants
- Mintaka: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
MSProgressive MSPhase 2Recruiting
ocrelizumab · Hoffmann-La Roche · 2026 · 360 participants
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
MSRelapsing and progressivePhase 4Running, not recruiting
ocrelizumab · Hoffmann-La Roche · 2025 · 60 participants
- MUSETTE: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
MSRelapsing MSPhase 3Running, not recruiting
methylprednisolone, ocrelizumab, terfenadine · Hoffmann-La Roche · 2020 · 864 participants
- MN39158: This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
MSMS (type not specified)Phase 3Completed
ocrelizumab · Hoffmann-La Roche · 2018 · 1,055 participants
- 20230309: Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
MSRelapsing MSPhase 3Running, not recruiting
ocrelizumab · Amgen · 2025 · 152 participants
- FENtrepid: A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
MSProgressive MSPhase 3Running, not recruiting
fenebrutinib · Hoffmann-La Roche · 2020 · 985 participants
- WA39085: A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
MSRelapsing MSPhase 2Running, not recruiting
ocrelizumab · Hoffmann-La Roche · 2020 · 23 participants
- AMS05: Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
MSRelapsing MSPhase 4Running, not recruiting
ocrelizumab · National Institute of Allergy and Infectious Diseases (NIAID) · 2023 · 123 participants
- WINDOCRE: Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial
MSMS (type not specified)Phase 3Running, not recruiting
Fondation Ophtalmologique Adolphe de Rothschild · 2023 · 244 participants
- A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice
MSMS (type not specified)Recruiting
Novartis Pharmaceuticals · 2026 · 7,466 participants
- DanNORMS: Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
MSRelapsing and progressivePhase 3Running, not recruiting
acetaminophen, fexofenadine, methylprednisolone +1 · Copenhagen University Hospital, Rigshospitalet · 2021 · 600 participants
- CN46182: Study of an On-Body Injection System for Home Use of Ocrelizumab in People with Multiple Sclerosis
MSMS (type not specified)Phase 3Running, not recruiting
F. Hoffmann-La Roche AG · 2026 · 54 participants
- OCARINA 3: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
MSRelapsing and progressivePhase 1Running, not recruiting
ocrelizumab · Hoffmann-La Roche · 2024 · 75 participants
- Ocarina II: A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
MSRelapsing and progressivePhase 3Completed
ocrelizumab · Hoffmann-La Roche · 2022 · 236 participants
- GAVOTTE: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
MSProgressive MSPhase 3Running, not recruiting
methylprednisolone, ocrelizumab, terfenadine · Hoffmann-La Roche · 2020 · 769 participants
- CONSONANCE: A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
MSProgressive MSPhase 3Running, not recruiting
ocrelizumab · Hoffmann-La Roche · 2018 · 927 participants
- Operetta 2: A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
MSRelapsing MSPhase 3Running, not recruiting
ocrelizumab · Hoffmann-La Roche · 2022 · 188 participants
- BLOOMS: B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis
MSRelapsing MSPhase 4Running, not recruiting
ocrelizumab · Amsterdam UMC, location VUmc · 2022 · 296 participants
- CCYB704A12301: Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
MSRelapsing and progressivePhase 3Running, not recruiting
ocrelizumab · Sandoz · 2025 · 183 participants
- REFINE-MS: A study to find out the best length of time between ocrelizumab doses for patients with relapsing remitting multiple sclerosis using a trial design with multiple groups and multiple stages
MSRelapsing MSPhase 3Ongoing (inferred)
2026 · 540 participants
- A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients
MSMS (type not specified)Completed
Novartis Pharmaceuticals · 2024 · 2,604 participants
- Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
MSRelapsing MSPhase 4Recruiting
ublituximab · Johns Hopkins University · 2026 · 50 participants
- MINORE: A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy
MSEarly (CIS/RIS)Phase 4Completed
ocrelizumab · Hoffmann-La Roche · 2022 · 70 participants
- Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS
MSRelapsing MSPhase 4Running, not recruiting
rituximab · Amsterdam UMC · 2023 · 200 participants
- WINDOCRE: For patients with active multiple sclerosis, impact of annual versus semi-annual infusions of ocrelizumab after 2 years of initial treatment on the absence of radiological disease activity at 2 years: a multicentre randomised controlled non-inferiority trial
MSRelapsing and progressivePhase 3Recruiting
ocrelizumab · Hopital Fondation Adolphe De Rothschild · 2023 · 244 participants
- OCREFINA: Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis
MSRelapsing MSPhase 4Enrolling by invitation
ocrelizumab · University of California, San Francisco · 2025 · 5 participants
- People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
MSRelapsing and progressiveRecruiting
glp-1, ocrelizumab · Northwestern University · 2025 · 100 participants
- ORATORIO-CP: Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
MSProgressive MSCompleted
State University of New York at Buffalo · 2023 · 732 participants
- O'HAND: A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
MSProgressive MSPhase 3Running, not recruiting
ocrelizumab · Hoffmann-La Roche · 2019 · 1,013 participants
- MuSicalE: Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
MSRelapsing and progressiveCompleted
ocrelizumab · Hoffmann-La Roche · 2018 · 1,710 participants
- PEACE: Evaluation of autonomy and care experience in multiple sclerosis when initiating subcutaneous ocrelizumab
MSRelapsing MSNot a drug-phase studyOngoing (inferred)
2026 · 750 participants
- Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab
MSRelapsing MSPhase 4Completed
ocrelizumab · Genentech, Inc. · 2020 · 179 participants
- TRIO: RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
MSRelapsing and progressivePhase 3Recruiting
rituximab · Rennes University Hospital · 2023 · 386 participants
- IMPACT MS: Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset
MSRelapsing MSPhase 4Running, not recruiting
ocrelizumab · University of California, San Francisco · 2020 · 30 participants
- SOPRANINO: A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab
MSEarly (CIS/RIS)Phase 4Completed
ocrelizumab · Hoffmann-La Roche · 2021 · 26 participants
- Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation
MSRelapsing MSPhase 4Completed
Massachusetts General Hospital · 2020 · 22 participants
- Ocrelizumab Access by Socio-Economic Status
MSRelapsing and progressiveCompleted
ocrelizumab · Brigham and Women's Hospital · 2021 · 800 participants
- ML45855: Assessing the Effects of Ongoing Ocrelizumab (OCR) Therapy on Fatigue and Cognition in Veterans With Multiple Sclerosis
MSMS (type not specified)Not a drug-phase studyNot yet recruiting
Anza Memon · 2025 · 30 participants
- FNO-RS2-OCREPRIPRO: The use of therapeutic monitoring of ocrelizumab serum concentrations for personalized pharmacotherapy of relapsing-remitting and primary progressive multiple sclerosis
MSRelapsing and progressivePhase 4Recruiting
ocrelizumab · Fakultni Nemocnice Ostrava · 2025 · 100 participants
- BN44083: A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Ascending Intravenous Doses of Glofitamab, Administered after Ocrelizumab Pretreatment, in Patients with Multiple Sclerosis
MSMS (type not specified)Phase 1Completed
F. Hoffmann-La Roche AG · 2023 · 5 participants
- Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf
MSRelapsing MSCompleted
Novartis Pharmaceuticals · 2022 · 168 participants
About this data
Where the data comes from
ClinicalTrials.gov, the EU Clinical Trials Register, ISRCTN, ChEMBL and Europe PMC, combined into the MSFrontier trial bank.
How it is collected
Registry records are collected automatically, duplicate records across registries are merged, and treatments, phases and populations are tagged by software from the registry data. When an error is reported, we fix the rule so the fix applies to every trial, and log it in the Corrections log.
Last update
Trial bank updated recently. Sources and corrections
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error